(f)MRI parameters and the relation with cognitive and emotional dysfunction in patients after treatment for M. Cushing and a comparison with patients with anxiety and depression

(f)MRI parameters and the relation with cognitive and emotional dysfunction in patients after treatment for M. Cushing and a comparison with patients with anxiety and depression - (f)MRI in Cushing's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36638

Enrollment

Registered

2011-04-01

Start date

2012-01-02

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cushing's disease hypercortisolism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - men and women between 18 and 55 years of age - patients treated for M. Cushing by transsphenoidal surgery with or without additional radiotherapy - adequately substituted - patients should be prepared and well informed about the study - patients should sign the informed consent

Exclusion criteria

Exclusion criteria: - difficulty to understand the Dutch language - history of contusio cerebri - presence of non-endocrinological impairments which could influence brainstructure or function - chronic misuse of alcohol or drugs - medication (other than suppletion) that could influence perfusion or cognition and can not be stopped two days before the scan takes place, with exclusion of SSRI in stable dossage - contraindications for MRI, such as metal implants, heart arrhythmia, claustrophobia etc.

Design outcomes

Primary

Measure	Time frame
I. What are the (irreversible) effects of M. Cushing on the brain and what is the correlation with psychopathology and cognition? It is expected that in patients with treated M. Cushing, abnormalities will be found in emotion regulation circuitry (parts of the prefrontal cortex, cingulate cortex, basal ganglia, hippocampus and amygdala) compared with matched controls. II. Are there shared and unique structural and functional MRI abnormalities in patients with treated M. Cushing and in patients with mood and anxiety disorders? It is expected that after treatment for M. Cushing, comparable cerebral impairment with comparable correlates with psychopathology are found as in patients with mood and anxiety disorders, compared to controls. III: Are there any effects of common polymorphisms of genes important for the stress system on the shared and unique functional and structural MRI abnormalities in patients treated for M Cushing and NESDA participants? It is expected that certain polymorphisms are associated with more pronounced variations and more psychopathology in both treated M. Cushing and depression and anxiety patients, based on a stronger predisposition to dysregulation of the HPA axis, or a greater sensitivity to the harmful effects of high cortisol levels.	—

Measure

Time frame

I. What are the (irreversible) effects of M. Cushing on the brain and what is the correlation with psychopathology and cognition? It is expected that in patients with treated M. Cushing, abnormalities will be found in emotion regulation circuitry (parts of the prefrontal cortex, cingulate cortex, basal ganglia, hippocampus and amygdala) compared with matched controls. II. Are there shared and unique structural and functional MRI abnormalities in patients with treated M. Cushing and in patients with mood and anxiety disorders? It is expected that after treatment for M. Cushing, comparable cerebral impairment with comparable correlates with psychopathology are found as in patients with mood and anxiety disorders, compared to controls. III: Are there any effects of common polymorphisms of genes important for the stress system on the shared and unique functional and structural MRI abnormalities in patients treated for M Cushing and NESDA participants? It is expected that certain polymorphisms are associated with more pronounced variations and more psychopathology in both treated M. Cushing and depression and anxiety patients, based on a stronger predisposition to dysregulation of the HPA axis, or a greater sensitivity to the harmful effects of high cortisol levels.

—

Countries

Netherlands

Outcome results